Most Read

Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody

Based in Cambridge of Massachusetts, Cadent Therapeutics is involved in the development of therapies to treat cognitive, mood, and movement disorders. Cadent will secure a $210m upfront payment,

The randomised, controlled and double-blind study will recruit 352 patients in between 25 and 30 medical centres and hospitals in North America. The multicentre study will evaluate the

PAH is a rare and chronic progressing disorder characterised by the narrowing of small pulmonary arteries and inflated blood pressure in the pulmonary circulation. Sotatercept, an investigational reverse-remodelling

Via newly established Swedish limited liability company Roar BidCo AB, EQT IX has announced a public offer of SEK220 ($26.1) in cash per share to the shareholders of

Leqvio, a first-in-class small interfering RNA (siRNA), has been approved based on data from the ORION clinical development programme. The approval allows to use Leqvio in combination with

Under the deal, Alexion shareholders will secure $60 in cash and 2.1243 new AstraZeneca American depositary shares (ADSs) listed on the Nasdaq exchange for each of their Alexion

NBE-Therapeutics is engaged in developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies by using its immune stimulatory iADC platform. NBE-002, the company’s lead compound, is presently in

The BNT162b2 vaccine has been granted authorisation under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to Covid-19. Canada is